Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis Depends on Age at Treatment Start
Neurol 92:e83-e95, Stelten, B.M.L.,et al, 2019
Diagnosis and Management of the Antiphospholipid Syndrome
NEJM 378:2010-2021, Garcia, D. & Erkan, D., 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Dual Antiplatelet Therapy with Aspirin and Clopidogrel for Acute High Risk Transient Ischaemic Attack and Minor Ischaemic Stroke: A Clinical Practice Guideline
BMJ 363:k5130, Prasad, K.,et al, 2018
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
NEJM 374: DOI:10.1056/NEJMoa1506930, Kernan, W.N.,et al, 2016
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome
Ann Neurol 79:560-568, Park, J.M.,et al, 2016
Ticagrelor Versus Aspirin in Acute Stroke or Transient Ischemic Attack
NEJM 375:35-43, Johnston, S.C.,et al, 2016
Effects of Aspiring on Risk and Severity of Early Recurrent Stroke After Transient Ischaemic Attack and Ischaemic Stroke: Time-Course Analysis of Randomised Trials
Lancet: 388:365-375, 312, Rothwell, P.M.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke
Stroke 46:1014-1023, Kwok, C.S.,et al, 2015
Effect of Clopidogrel with Aspirin on Functional Outcome in TIA or Minor Stroke
Neurol 85:573-579,562, Wang, X.,et al, 2015
Intracranial Atherosclerosis
Lancet 383:984-998, Qureshi, A. & Caplan, L.R., 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack
Stroke 45:2160-2236, Kernan, W.N.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
NEJM 369:11-19,82, Wang, Y.,et al, 2013
Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013
Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013
Reduction in Early Stroke Risk in Carotid Stenosis with Transient Ischemic Attack Associated with Statin Treatment
Stroke 44:2814-2820, Merwick, A.,et al, 2013
Cerebrovascular Complications of Neurocysticercosis
The Neurologist 18:17-22, Marquez, J.M. and Arauz, A., 2012
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
NEJM 367:817-825, The SPS3 Investigators, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
Lancet 377:2013-2022, Bousser, M.G.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Efficacy and Safety of Combination Antiplatelet Therapies in Patients with Symptomatic Intracranial Atherosclerotic Stenosis
Stroke 42:2883-2890, Kwon, S.U.,et al, 2011
Population-Based Study of Behavior Immediately After Transient Ischemic Attack and Minor Stroke in 1000 Consecutive Patients: Lessons for Public Education
Stroke 41:1108-1114, Chandratheva,A.,et al, 2010
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Incidence of Cerebral Microbleeds: A Longitudinal Study in Memory Clinic Population
Neurol 74:1954-1960, Goos,J.D.C., et al, 2010
Effect of Home Testing of International Normalized Ratio on Clinical Events
NEJM 363:1608-1620, Matchar,D.B.,et al, 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Effect of Age on Stroke Prevention Therapy in Patients with Atrial Fibrillation: The Atrial Fibrillation Investigators
Stroke 40:1410-1416, van Walraven,C.,et al, 2009
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009